Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ANGLE hails results from landmark ovarian cancer study which underlines potential of its liquid biopsy

Its Parsortix system was able to detect cancer in 95% of the cases, achieving a lower false positive rate than existing method of detection
ANGLE hails results from landmark ovarian cancer study which underlines potential of its liquid biop
The technology could ultimately help dictate treatment options, streamlining the process

AIM-listed med-tech firm ANGLE plc (LON:AGL,OTCQX:ANPCY) said its ground-breaking liquid biopsy outperformed the current tests used to tell whether a pelvic mass is malignant or benign.

Its Parsortix system was able to detect cancer in 95% of the cases, achieving a lower false positive rate than existing method of detection.

WATCH: ANGLE boss delighted by study results

READ: Our Big Picture overview of the company

ANGLE’s technology was used in harness with a specially-developed algorithm using certain patient data.

Results came from a study of 400 people at two centres – Vienna and New York State.

ANGLE believes the Parsortix blood test has the potential to aid the diagnosis of ovarian cancer before a biopsy or surgery is performed.

Diagnosis before biopsy

Why does this matter? Well, it will allow those with disease to be referred directly to gynaecologic oncology surgeons.

At the same time, it should ensure patients with benign tumours are be cared for in their communities. 

This streamlined strategy has the potential to cut costs and accelerate treatment.

ANGLE’s founder and chief executive said of the latest results: “This success enables ANGLE to move forward into the validation phase for the use of Parsortix in its first clinical application. 

“We believe ANGLE is building momentum towards securing a leading and well differentiated commercial position in the emerging multi-billion dollar liquid biopsy market."

---adds CEO interview---

 

View full AGL profile View Profile

ANGLE plc Timeline

Related Articles

picture of drug research
13:20
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
genomics.jpg
October 04 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use